MedTrace Logo

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

NCT03780959 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2019-08-02

Study results available
· View outcomes & findings →

Summary

The primary objective of this study was to determine the efficacy of etanercept in children with polyarticular course JRA.

Conditions

  • Juvenile Rheumatoid Arthritis

Interventions

DRUG

Etanercept

Administered twice weekly by subcutaneous injection

DRUG

Placebo

Administered twice weekly by subcutaneous injection

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-05-01
Primary Completion
1998-07-08
Completion
1998-07-08
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03780959 on ClinicalTrials.gov